Journal of Cardiac Failure
Volume 13, Issue 6 , Pages 437-444 , August 2007

Baseline and Serial Neurohormones in Patients With Congestive Heart Failure Treated With and Without Bucindolol: Results of the Neurohumoral Substudy of the Beta-Blocker Evaluation of Survival Study (BEST)

  • Robert P. Frantz, MD

      Affiliations

    • From the Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota
    • Corresponding Author InformationReprint requests: Robert P. Frantz, MD, Division of Cardiovascular Diseases, Mayo Clinic, 200 1st St SW, Rochester MN 55905.
    • ,
  • Brian D. Lowes, MD

      Affiliations

    • University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • Paul A. Grayburn, MD

      Affiliations

    • Current affiliation: Baylor University Medical Center, Dallas, Texas.
    • VAMC Dallas, Dallas, Texas
    • ,
  • Michel White, MD

      Affiliations

    • Montreal Heart Institute, Washington, DC
    • ,
  • Heidi Krause-Steinrauf, MS

      Affiliations

    • George Washington University, Washington, DC
    • ,
  • Vaishali Krishnan, BS

      Affiliations

    • VA Cooperative Studies Program, Palo Alto, California
    • ,
  • Lauren Uyeda, MA

      Affiliations

    • VA Cooperative Studies Program, Palo Alto, California
    • ,
  • John C. Burnett, MD

      Affiliations

    • From the Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota
    • ,
  • for the BEST Neurohumoral Substudy Investigators

Received 29 September 2006 ,Revised 6 March 2007 ,Accepted 16 March 2007.

References 

  1. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  2. Nakaoka H, Kitahara Y, Amano M, Imataka K, Fujii J, Ishibashi M, et al. Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 1987;10:221–225
  3. Yoshimoto T, Naruse M, Tanabe A, Naruse K, Seki T, Imaki T, et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. Endocrinology. 1998;139:81–88
  4. Luchner A, Burnett JCJ, Jougasaki M, et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998;32:1839–1844
  5. Tanaka M, Ishizaka Y, Ishiyama Y, Kato J, Kida O, Katamura K, et al. Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertension Res. 1996;19:239–245
  6. Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy: The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. The RESOLVD Investigators. Circulation. 2000;101:378–384
  7. Yasue H, Yoshimura M, Sumida H, et al. Localization and secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–293
  8. Wei CM, Lerman A, Rodeheffer RJ, McGregor CGA, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation. 1994;89:1580–1586
  9. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;35:997–1001
  10. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol. 2002;39:1615–1622
  11. Persson H, Andreasson K, Kahan T, Eriksson SV, Tidgren B, Hjemdahl P, et al. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Failure. 2002;4:73–82
  12. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001;38:436–442
  13. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633–641
  14. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293–1299
  15. Van Beneden R, Gurne O, Selvais P, et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: 7 year follow-up study. J Cardiac Failure. 2004;10:490–495
  16. Omland T, Lie R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573–1579
  17. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504–509
  18. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. For the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292–299
  19. Gheorghiade M, Adams KF, Gattis WA, Teerlink JR, Orlandi C, O'Connor CM. Surrogate end points in heart failure trials. Am Heart J. 2003;145(2 Suppl):S67–S70
  20. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283
  21. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;70:e23–e30
  22. Packer M, McMurray J, Massie B, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe CHF: Results of a pilot study. J Cardiac Failure. 2005;11:12–20
  23. Gottlieb S. The impact of finally publishing a negative study: New conclusions about endothelin antagonists. J Cardiac Failure. 2005;11:21–22
  24. Lüscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: the Heart Failure ETA Receptor Blockade Trial (HEAT). Circulation. 2002;106:2666–2672
  25. Piuhola J, Szokodi I, Kinnunen P, et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension. 2003;41:93–98
  26. Beta-Blocker Evaluation of Survival Trial Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667
  27. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003;107:1100–1102
  28. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang C-S, Lindenfeld J, Lowes BD, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the Beta-Blocker Evaluation of Survival Trial Circulation. 2004;110:1437–1442
  29. Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, et al. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol. 2005;96:698–704
  30. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation. 2006;113:977–985
  31. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J. 2005;149:541–547
  32. Fujimora M, Yasumara Y, Ishida Y, et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Cardiac Failure. 2000;6:3–10
  33. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 2001;141:925–932
  34. Latini R, Masson S, Anand A, Judd D, Maggioni A, Chiang Y, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial. Circulation. 2002;106:2454–2458
  35. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52:1528–1538

 BEST was sponsored by the Division of Epidemiology and Clinical Applications of the National Heart, Lung and Blood Institute and the Department of Veterans Affairs Cooperative Studies Program through an interagency agreement. Additional support was provided by Incara Pharmaceuticals Corporation, which also supplied bucindolol and placebo. The authors have no conflicts of interest or relevant financial disclosures to report.

PII: S1071-9164(07)00098-X

doi: 10.1016/j.cardfail.2007.03.007

Journal of Cardiac Failure
Volume 13, Issue 6 , Pages 437-444 , August 2007

Article Tools

* Image Usage & Resolution